In an analysis of a large cohort of patients with high-risk melanoma, Tarhini et al. reported that baseline S100b levels were significantly associated with RFS [HR 1.70 (95% CI, 1.21 to 1.92; p < 0.001)] and OS [HR 1.44 (95% CI, 1.06 to 1.95; p = 0.0210)], where higher values signified a worse prognosis [43]. The gene discussed is S100B; the disease is melanoma.